Back to Search
SETH ROSENTHAL, M.D.
M.D.
Radiation Oncology Physician
NPI: 1881690584IndividualAccepts Medicare
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1987
Research & Publications (20)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
PMID 18990504·Int J Radiat Oncol Biol Phys·2009
3-trial
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
PMID 11272670·Tech Urol·2001
6-review
Australian men's experiences during a microbicide male tolerance study.
PMID 19085229·AIDS Care·2009
3-trial
Statement 4: therapy should be offered to children with idiopathic short stature (ISS) whose heights are < -2.25 standard deviation (SD) score.
PMID 18438328·Pediatr Endocrinol Rev·2008
6-review
Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes.
PMID 18710678·J Adolesc Health·2008
8-other
Treatment perspectives in idiopathic short stature with a focus on IGF-I deficiency.
PMID 17581497·Pediatr Endocrinol Rev·2007
6-review
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection.
PMID 16581745·Sex Transm Infect·2006
4-observational
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction.
PMID 17261972·Pediatr Endocrinol Rev·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2801 K ST, SUITE 502
SACRAMENTO, CA 95816 - Phone
- (877) 515-0053
Quick Facts
- NPI
- 1881690584
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile